Nutra Pharma Corp. Posts $1.56M Net Loss Through Q3 2025 as Expenses Outpace Sales

Nutra Pharma Corp., a pharmaceutical company, reported a net loss of $1.56 million for the nine months ending September 30, 2025, compared to a loss of $1.05 million for the same period in 2024. The loss widened by $504,110, or 48%, as operating expenses grew faster than revenue. Read more earnings reports.

Revenue for the nine-month period climbed to $228,748 from $164,436 in the prior year, an increase of $64,312 or 39%. For the three months ending September 30, 2025, revenue totaled $70,242, down slightly from $74,994 in the third quarter of 2024.

Operating expenses surged to $1.20 million for the nine months ending September 30, 2025, up from $860,289 in the year-ago period. For the third quarter alone, operating expenses jumped to $420,652 from $255,445, an increase of 65%.

The company posted an operating loss of $996,424 for the nine-month period, compared to an operating loss of $699,554 in 2024. Third-quarter operating loss reached $356,076, nearly doubling from the $184,752 loss reported in the same quarter last year.

Gross profit for the nine months ending September 30, 2025 stood at $208,535, compared to $160,735 in the prior year. Cost of goods sold rose to $117,706 from $64,885.

Cash used in operations totaled $944,146 for the nine-month period, a significant increase from the $245,749 used in the same period of 2024. The company raised $962,354 from financing activities during the nine months, offsetting the operational cash burn.

Total assets increased to $709,853 as of September 30, 2025, up from $599,495 at year-end 2024. Current assets rose to $545,106 from $374,837. Total liabilities climbed to $17.06 million from $15.41 million.

Stockholders' deficit deepened to $16.35 million as of September 30, 2025, compared to a deficit of $14.81 million at the end of 2024. Retained deficit widened to $77.79 million from $76.23 million. The company had 7.1 billion common shares outstanding as of September 30, 2025.